G-Link CAR-T Delivery Platform Showcased at ASGCT
Vyriad unveiled its G‑Link CAR‑T delivery platform at the ASGCT meeting, showcasing a modular protein adapter that repurposes existing lentiviral vectors for in‑vivo use. The technology promises to cut development timelines by eliminating extensive vector redesign and to boost transduction efficiency in both in‑vivo and ex‑vivo settings. Vyriad’s VV169 in‑vivo CAR‑T program is slated for clinical initiation later this year, while G‑Link moves toward broader clinical translation. The company aims to replace lengthy manufacturing cycles with off‑the‑shelf immunotherapies.
FDA Approval of DOR/ISL Expands HIV Treatment Options Beyond INSTIs: Amy Colson, MD, MPH
The FDA has approved Idvysno, a two‑drug regimen of doravirine and islatravir (DOR/ISL), marking the first HIV therapy that omits both integrase strand transfer inhibitors (INSTIs) and tenofovir. Clinical trials showed non‑inferior viral suppression at 48 weeks compared with standard...
Single Psilocybin Dose Triggers Month-Long Brain Changes and Mood Boosts
Researchers at the University of California‑San Francisco and Imperial College London reported that a single 25 mg dose of psilocybin produces measurable increases in brain entropy and white‑matter integrity that persist for at least a month, while participants report heightened insight...
Oculis Gains FDA SPA for PIONEER-1 Trial of Privosegtor in Optic Neuritis
Oculis Holding AG announced that the U.S. FDA has granted a Special Protocol Assessment for its PIONEER-1 Phase 3 trial of Privosegtor in optic neuritis. The SPA confirms the study design and primary endpoint, moving the company closer to a...
Polygenic Risk Score Predicts Eight Cardiovascular Conditions
A new polygenic risk score (PRS) predicts eight cardiovascular conditions, including coronary artery disease and atrial fibrillation, with odds ratios as high as 41.0. The assay, orderable from a blood or saliva sample, was validated in 53,306 participants and demonstrated...
Early Postoperative Inflammatory Markers Predict Major Complications After Rectal Cancer Surgery
A prospective cohort of 98 rectal cancer patients measured CRP and NLR at 24 and 48 hours after surgery. Elevated CRP at 48 hours strongly predicted major complications, while NLR showed no significant predictive value. Open surgery was linked to...
Molecular Quantum Nanosensors Map Temperature Inside Living Cancer Cells
A team from Japan's National Institutes for Quantum Science and Technology introduced molecular quantum nanosensors (MoQNs) that map temperature and radical activity inside living cancer cells with 0.3 °C precision, a threefold boost over existing nanodiamond probes. The breakthrough promises finer...
The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine
Aptevo Therapeutics reported an 87% clinical benefit rate and 81% remission in its Phase 1b AML RAINIER study, combining mipletamig with venetoclax and azacitidine. Entrada Therapeutics disclosed positive Phase 1/2 data for ENTR‑601‑44, showing functional gains and increased dystrophin in Duchenne patients...
FDA Approves Otarmeni, First Gene Therapy to Restore Hearing in OTOF‑Related Deafness
The U.S. Food and Drug Administration has cleared Regeneron’s Otarmeni, the first gene‑therapy drug to treat genetic hearing loss. The treatment targets OTOF‑related deafness, a condition that affects roughly 200,000 people globally, and promises to restore natural hearing when administered...
Gene Therapy Restores Walking After Paralysis
Researchers at the University Hospital Cologne used a designer cytokine, hyper‑interleukin‑6 (hIL‑6), delivered via an AAV2 viral vector into the motor cortex of mice with spinal‑cord contusions. The protein traveled transneuronally to brainstem serotonergic neurons, prompting intact fibers to sprout...
DUET Trial: Low-Sodium Oxybate Significantly Consolidates Nighttime Sleep Architecture in Narcolepsy
The phase‑4 DUET trial showed that low‑sodium oxybate (LXB, Xywav) markedly consolidates nighttime sleep in narcolepsy type 1 and type 2 patients. Objective polysomnography recorded a 45‑minute increase in deep N3 sleep, 13 fewer stage transitions and three fewer awakenings per night....
Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus
Scientists at the La Jolla Institute for Immunology have isolated the first human monoclonal antibodies that can neutralize measles virus. The antibodies, derived from a vaccinated donor, bind the virus' hemagglutinin and fusion proteins, blocking entry into cells. In a...
Cellular Origins Collaborates with Immatics on Automation for Cell Therapy Manufacturing
Cellular Origins has partnered with immuno‑oncology firm Immatics to integrate its Constellation® automated mobile robotic platform into select steps of Immatics’ cell‑therapy manufacturing workflow. The joint effort will test how robotics can boost efficiency, scalability and cost‑effectiveness for next‑generation therapies,...
Stem Cell-Derived Islet Therapies Target Type 1 Diabetes Challenges
Sana Biotechnology is leveraging hypoimmune cell engineering to create allogeneic, stem‑cell‑derived pancreatic islet‑like cells that can evade both adaptive and innate immune attacks. The company aims to deliver a single intramuscular injection that restores normal blood‑sugar control for type 1 diabetes...
Aptevo Reports Strong Remission Data in Frontline AML Trial as RAINIER Study Advances Toward Phase 2
Aptevo Therapeutics disclosed Phase 1b data from its RAINIER trial, showing mipletamig combined with venetoclax and azacitidine achieved an 87% clinical benefit rate and an 81% composite remission rate in 31 frontline AML patients. The regimen produced a 65% complete remission...
Targeting Ischemic Disease with DiaMedica CEO Rick Pauls — Episode 254
DiaMedica Therapeutics, led by CEO Rick Pauls, is advancing a recombinant KLK1 protein to treat ischemia‑driven diseases such as preeclampsia, fetal growth restriction, and acute ischemic stroke. The podcast episode highlights the company’s focus on restoring vascular blood flow and...
Polyphasic in Vitro Characterization of the Pigment-Producing Microfungus Rhodotorula Sp. For Potential Application as a Probiotic in Mariculture
Researchers isolated a pigment‑producing Rhodotorula sp. from mangrove leaves in southern India and applied a polyphasic in‑vitro framework to assess its probiotic suitability for mariculture. The strain generated 0.73 g L⁻¹ dry biomass, accumulated up to 398 µg g⁻¹ carotenoids, and displayed strong antioxidant...
Asembia AXS26: How Drug Innovation Could Strain Access Systems
In a follow‑up interview at the Asembia AXS26 summit, Aradigm Health CEO Will Shrank warned that emerging therapies priced above $1 million per patient could overwhelm existing market‑access and financing frameworks. He highlighted upcoming treatments for type 1 diabetes, wet macular degeneration...
Opentrons Debuts Simulation and Visualization for AI-Generated Lab Workflows
Opentrons Labworks introduced Protocol Visualization for Flex, a new simulation and visualization layer built into Opentrons App version 9.0 and slated for release in April 2026. The tool lets scientists preview AI‑generated, Python‑API, or Protocol Designer workflows in a dynamic virtual deck,...
Remembering J. Craig Venter, PhD
In this tribute episode of Touching Base, host Corinna Singelman and Gen editors John Sterling and Kevin Davis reflect on the life and legacy of biotech pioneer J. Craig Venter, who recently died at 79. They recount Venter's groundbreaking role...
Moderna CEO Labels Spike Protein “Garbage” In New Vaccine
Whoa. 🫣 This is incredible. Stephen Hoge, president of Moderna, gave an interview on April 17 to the "why should I trust you?" podcast in which he referred to the spike protein — famously in all the Covid vaccines —...
FDA Turmoil Casts Shadow Over Gene‑Therapy Conference in Rome
At the Alliance for Regenerative Medicine’s meeting in Rome, industry leaders grappled with heightened U.S. regulatory uncertainty after the FDA’s cell‑and‑gene therapy rejection rate doubled since 2024 and the agency’s top gene‑therapy regulator, Vinay Prasad, left. Recent approvals for rare‑disease...
TerraPower Isotopes Breaks Ground on $450 Million Actinium‑225 Plant in Philadelphia
TerraPower Isotopes broke ground on a $450 million, 250,000‑square‑foot Actinium‑225 manufacturing plant in Philadelphia, a move that will increase global supply twentyfold. The flagship Bellwether Laboratory aims to support next‑generation alpha‑particle cancer treatments and create roughly 225 permanent jobs.
Just ‘Stay Alive for the Next 10 Years’ – Anti-Ageing Drugs Are Coming, Says Billionaire Investor
Billionaire investor Jim Mellon told attendees at Spear’s 500 Live that the first truly anti‑ageing drugs could hit the market within a decade. He highlighted clinical‑stage senolytics, partial genetic reprogramming and repurposed weight‑loss medicines as the leading candidates to halt...
Eli Lilly Adds $4.5 B to Indiana Plant Portfolio, Launches First Genetic Medicine Facility
Eli Lilly announced a $4.5 billion expansion across two Lebanon, Indiana sites and opened Lilly Lebanon Advanced Therapies, its first dedicated genetic‑medicine manufacturing plant. The move lifts the company’s cumulative Indiana capital commitments since 2020 to more than $21 billion, underscoring a...
Parallel 3D Bioprinting Builds Tissue Model Arrays in Minutes
Researchers have introduced a slippery‑liquid‑infused porous surface (SLIPS) droplet microarray that enables parallel digital light processing (DLP) bioprinting of hydrogel tissue models. By removing physical walls and using hydrophilic spots on a superhydrophobic background, the system prints dozens to hundreds...
EnGene's Shares Crash on Updated Pivotal Bladder Cancer Data
EnGene Therapeutics reported Phase 2 data for its experimental bladder‑cancer therapy that revealed a modest 5% objective response rate and safety signals in more than half of patients. The results triggered an 80% plunge in the Canadian biotech’s stock, wiping...
AI Poised to Spark Trillion‑dollar Biotech Revolution
Last day @synbiobeta and had a fascinating discussion with my friend @andrewhessel about the SynBio space. His insight was that SynBio and Biotech feels very much like the AI space pre LLM acceleration. AI will accelerate Biotech and Genetic Agency. Today's biotech...
Blackstone Puts $250M Into Anagram to Tackle Cystic Fibrosis Complication
Blackstone Life Sciences announced a $250 million investment in Anagram, a biotech developing a novel therapy for a cystic fibrosis complication. The capital, drawn from one of the industry’s largest private life‑science funds, will accelerate Anagram’s late‑stage clinical trials, manufacturing scale‑up,...
Can OpenAI’s GPT Rosalind Tackle Data Challenges in Life Sciences Research?
OpenAI has unveiled GPT‑Rosalind, a large language model tailored for life‑science research that can reason across literature, biological databases, and experimental data. In internal tests the model led benchmark BixBench, showing superior multi‑step bioinformatics performance compared with earlier OpenAI models....
Entrada Stock Falls on Duchenne Data; Wegovy Expands Access
Entrada Therapeutics reported topline results from its Duchenne muscular dystrophy (DMD) cohort of six patients, showing no meaningful functional improvement. The disappointing data sent Entrada's shares down roughly 15% in after‑hours trading. Meanwhile, Novo Nordisk announced expanded payer coverage for...
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed’s newly launched lung drug Brinsupri posted first‑quarter sales of $208 million, beating sell‑side forecasts but falling short of the $230 million buy‑side target. The miss triggered a near‑17% plunge in the stock, sending shares to $114.25, their lowest level since August....
Genetic Testing May Unlock Vitamin D's Potential for Diabetes Prevention
A JAMA Network Open analysis of the D2d trial shows that daily 4,000 IU vitamin D₃ reduced type 2 diabetes incidence by 19% among prediabetic adults carrying the ApaI AC or CC variants of the vitamin D receptor gene. The same high‑dose regimen had...
The FDA's One-Day Inspection Pilot Is Already Running
The FDA launched a one‑day inspection pilot announced by Commissioner Marty Makary, with roughly 46 screening assessments completed since April across food, biologics, medical devices and clinical research sites. Most assessments resulted in a No Action Indicated outcome, though a...
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
Atara Biotherapeutics and Pierre Fabre’s EBV‑positive PTLD cell therapy Ebvallo received a regulatory U‑turn after FDA CBER director Vinay Prasad stepped down. The agency now says a single‑arm study with an appropriate historical control can satisfy the “adequate and well‑controlled” requirement, allowing...
Electric‐Eel‐Inspired Ionic Power Source Microneedles With Self‐Reporting Structural Colors for Wound Healing
Researchers have engineered ionic power source microneedles (IPSMs) that combine electric‑eel‑inspired ion transport with chameleon‑like structural colors for wound care. The three‑layer device creates an internal K⁺‑driven electric field, delivering electrical stimulation that accelerates tissue repair. Integrated silver nanoparticles provide...
Transforming CTMS: An Operating Layer for Real-Time Trial Execution
Clinical trial management systems (CTMS) are evolving from static record‑keeping tools into an operating layer that adds real‑time, AI‑driven reasoning to coordinate complex, multi‑system studies. The article highlights that Phase III trials now span a median of more than ten countries,...
AI and Robotics Reshape IVF, Eye Gene Editing
Researchers are using AI to identify promising sperm and embryos, developing robotic systems that could automate parts of the IVF process, and even exploring controversial genetic editing techniques designed to prevent inherited disease.
STING Pathway Emerges as New Cancer Immunotherapy Frontier
The number of new potential ways to rev up the immune response to cancer keeps expanding. Today it's STING-ing it. @ScienceMagazine https://t.co/p9g0Mmc8kG https://t.co/LbKfODQkO1
3D-MIND: A Flexible Device that Can Be Integrated with Living Brain Cells
Researchers at Princeton have unveiled 3D-MIND, a flexible electronic mesh that can be embedded inside three‑dimensional cultures of living brain cells. The device integrates sensors and micro‑stimulators within the neural tissue, enabling stable recording and stimulation for up to six...
CAPR Sues NS Pharma over Launch Delays, Pricing Disputes
$CAPR is suing NS Pharma, its deramiocel commercial partner. Capricor alleges NS Pharma is not doing enough to prepare for commercial launch + some pricing mishegas. 8K https://t.co/7iFyLRhKsq
International Team Launches Hantavirus Vaccine Development
JUST IN: Scientists from the UK, US, and South Africa formed a team to develop a hantavirus vaccine, per BBC
Funding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer Immunotherapies
Kanvas Biosciences and LTZ Therapeutics announced a combined $86 million financing round to accelerate next‑generation cancer immunotherapies. Kanvas closed a $48 million Series A to push its microbiome‑based platform and the lead candidate KAN‑001 toward clinical trials. LTZ secured $38 million to expand its...
Preprints Safeguard Vaccine Safety Data From FDA Suppression
"The Paper That Didn't Disappear" FDA reportedly held back several vaccine safety papers headed to publication. Fortunately, one was on medRxiv and remains available. Why preprints matter; my latest Substack: https://t.co/YfTbkEPBU4 Also discussed in #healthandveritas podcast. https://t.co/k24zPtoGA2
STAT Live Event in SF Featuring INSM and BBIO CEOs
Today is an opportune moment to mention STAT's next live event in San Francisco on May 19. I will be chatting on stage with $INSM CEO Will Lewis and $BBIO CEO Neil Kumar. Full agenda and registration here: https://t.co/YtXTTuz1Nv
Amgen Adds $300M to Puerto Rico Budget; Novartis to Exit Oral Drug Factory in Germany
Amgen announced an additional $300 million investment to expand its manufacturing footprint in Puerto Rico, bringing its total U.S. capital outlay to nearly $2 billion over the past year. The funding will support new bioprocessing lines and increase the island’s capacity for...
CRISPR Selectively Eliminates KRAS‑mutant Cancer Cells
The CRISPR Killer as in KRAS mutated cancer cells https://t.co/y1zrmYbIAQ Explainer thread @N8Krah co-author https://t.co/CIweqZMUqY
Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD
When choosing a frontline Bruton tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia, clinicians currently rely on FDA‑approved covalent agents, with acalabrutinib and zanubrutinib favored for their superior cardiovascular safety over ibrutinib. Emerging data from the 2025 ASH meeting show...
Hidden Microproteins Reshape Our View of Disease
"The human genome encodes for a new category of molecule" "The ‘dark proteome’ is upending our understanding of human disease" @Nature "Expanding the human proteome with microproteins and peptideins" https://t.co/5ncSKGKHBH https://t.co/2Rx65FJCbG @statnews @MeganMolteni https://t.co/7mATxNQ1EO @TheEconomist
STAT+: Pharmalittle: We’re Reading About Sanofi and an FDA Voucher, FDA Rethinking a Rejection, and More
Sanofi asked the FDA to withdraw its type 1 diabetes antibody teplizumab from the new fast‑track voucher program after Center for Drug Evaluation and Research director Tracy Beth Høeg publicly challenged a staff decision to approve the drug. The agency missed...